This phase 2 nonrandomized clinical trial evaluates the clinical activity and safety of the FOLFIRINOX regimen (leucovorin, fluorouracil, irinotecan, and oxaliplatin) as first-line treatment for patients with advanced gastroesophageal adenocarcinoma.
This secondary analysis evaluates the effect of adjuvant imatinib on overall survival in patients who have a high estimated risk for gastrointestinal stromal tumor recurrence after macroscopically complete surgery.
This randomized clinical trial examines the effect of savolitinib monotherapy compared with sunitinib monotherapy on progression-free survival in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma.
This cohort study examines the safety and efficacy of immune checkpoint inhibitor rechallenge in patients with metastatic renal cell carcinoma.
This cross-sectional study analyzed Medicare Part D prescriber files to determine changes in opioid prescribing patterns among oncologists and generalists between 2013 and 2017, during the opioid epidemic.
This interventional clinical trial examines the safety and tolerability of osimertinib and bevacizumab combination treatment and assesses the 12-month progression-free survival of the combination in patients with metastatic EGFR-mutant lung cancers.
A 75-year old woman with a history of follicular lymphoma and breast cancer presents with gradual vision loss and confusion; magnetic resonance imaging reveals hyperintensity in the left occipital and temporal lobes. What is your diagnosis?
This Viewpoint advocates for increased use of neoadjuvant therapy in the treatment of localized pancreatic adenocarcinoma.
This case series examines the results of implementing a universal microbiologic screening strategy for asymptomatic patients with cancer for coronavirus disease 2019 at 1 institution in the United Arab Emirates.
This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.
This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.
This cohort study examines national rates of neoadjuvant dual-agent chemotherapy and radiation followed by surgery in patients with locally advanced esophageal carcinoma after a randomized clinical trial demonstrated a survival advantage.
This Viewpoint highlights the importance of understanding the sources and variations in people’s notions of cancer risk.
This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.
This single-arm, multicenter phase 2 trial investigates the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer.
This systematic review and meta-analysis evaluates the association of immune checkpoint inhibitor treatment with overall response rate, disease control rate, overall survival, and progression-free survival in patients with microsatellite instability-high cancers.
This cohort study uses Surveillance, Epidemiology, and End Results data to assess if Medicaid expansion is associated with improved population-level survival in patients with non–small cell lung cancer.
This review evaluates best practices for developing and assessing the clinical utility of predictive computational methods in oncology.
This Viewpoint advocates for the consideration of hippocampal-sparing radiotherapy in patients with gliomas to mitigate treatment-related adverse events.
This cross-sectional study assesses the risk associated with Coronavirus Disease 2019 for pediatric patients with cancer.
This phase 2 randomized clinical trial evaluates the outcomes of combined immune checkpoint inhibition plus best supportive care vs best supportive care alone for patients with advanced colorectal cancer.
This double-blinded, randomized, placebo-controlled clinical trial evaluates the utility of olanzapine for treating chronic nausea/vomiting in patients with advanced cancer.
This study analyzes the incidence of opioid-associated deaths in cancer survivors vs the general population in the US from 2006 through 2016 using National Center for Health Statistics death certificate data.
This cohort study examines the association between prescription drug monitoring program mandates with and without a cancer exemption and the percent of oncologists’ patients with any opioid prescription covered by Medicare Part D.
This Viewpoint makes the case for health reform in the United States and calls on oncologists and other physicians to share their experiences, participate in the conversation, and help guide principles of reform.
This Viewpoint discusses the considerations and challenges affecting the palliative care specialty and delivery of palliative care in the COVID-19 era, as well as potential solutions.
This essay discusses similarities between a doctor’s experiences with diagnoses of cancer and coronavirus disease 2019 (COVID-19).
Create a personal account or sign in to: